Richard Gliklich, MD

Researchers are turning to patient registries to fill rare-disease knowledge gaps.

Similarities exist, but successful design requires that CROs understand the differences.

Registries could strengthen the postapproval safety net-critical in the current cautious environment.

A new paradigm that could transform a drug failure into a drug success would narrow the target population to those patients most likely to benefit from such treatment.